Moderate Evidence
Research Overview
Amycretin Research for Obesity
An evidence-based overview of research examining Amycretin in the context of obesity. This page synthesizes findings from peer-reviewed literature.
Research Summary
Amycretin Phase 1 trials demonstrated substantial weight loss in adults with obesity. Oral formulation showed ~13% weight loss at 12 weeks, while subcutaneous formulation achieved up to ~22% at 36 weeks. These signals exceed single-mechanism GLP-1 agonists at comparable timepoints, validating the dual-agonist approach.
Referenced Studies
Click any PMID to view the full study on PubMed.
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Always consult a healthcare provider before making health decisions.